Last updated: July 27, 2025
Introduction
Patent KR20150081339, filed in South Korea, represents a strategic intellectual property asset within the pharmaceutical industry. Precise understanding of its scope, claims, and surrounding patent landscape informs development strategies, licensing opportunities, and competitive positioning. This analysis dissects the patent's core claims, contextualizes its scope within pertinent patent ecosystems, and evaluates its influence on the ongoing patent landscape.
Patent Overview
The patent, titled "Method for Producing a Protein or Peptide," was filed in 2015 and issued subsequently, with publication number KR20150081339. Its primary focus encompasses an innovative method of producing proteins or peptides, particularly emphasizing efficiency, yield, and purity enhancements through novel biotechnological processes.
Relevant Classifications: This patent is classified under the Cooperative Patent Classification (CPC) codes C12P (fermentation or enzyme-using processes; enzyme preparation) and C12N (microorganisms or enzymes; mutation or genetic engineering; culture media), signaling its relevance to biotechnological processes involving recombinant DNA technology and fermentation.
Scope of the Claims
The claims of KR20150081339 define the boundaries of the invention critically. They generally encompass the following key aspects:
1. Methodological Claims
The main claims articulate a specific process for producing a target protein or peptide, involving:
- Genetic modification of host cells, such as bacteria or fungi, to incorporate recombinant DNA sequences coding for the desired protein.
- Cultivation under defined conditions, including particular media compositions, temperature ranges, pH levels, and fermentation parameters.
- Harvesting and purification techniques, emphasizing steps that improve yield and purity, potentially including specific purification reagents or chromatography techniques.
For example, a broad claim might specify the genetic constructs used, the fermentation parameters maintained within optimal ranges to maximize expression, and purification steps that result in higher purity levels compared to prior art.
2. Composition Claims
Secondary claims address compositions of matter, such as the recombinant expression vectors, genetically modified host cells, or the resultant proteins or peptides with particular characteristics (e.g., glycosylation patterns, activity levels).
3. Use Claims
Use claims specify the application of the produced proteins or peptides, such as their therapeutic efficacy, use in vaccine formulations, or as industrial enzymes.
Key Elements of the Claims
- The genetic constructs involve specific promoter and regulatory sequences, possibly novel or optimized for improved expression.
- The fermentation process parameters are precise and novel, such as specific pH cycles, oxygen levels, or nutritional regimes that differ from prior art.
- The purification process may involve innovative steps or materials, enabling superior yield or purity.
Patent Landscape Context
1. Related Patents and Prior Art
The patent landscape surrounding KR20150081339 includes several related filings, notably in the US, Europe, and other Asian jurisdictions. Critical prior art encompasses:
- Recombinant protein production patents: Existing patents describe expression systems using Escherichia coli, Saccharomyces cerevisiae, or mammalian cells.
- Process optimization patents: Techniques for optimizing fermentation conditions and purification steps are well-documented but often lack the specific combination or novel parameters claimed here.
- Genetic construct patents: Prior art includes vectors with specific promoters; novelty in KR20150081339 may stem from unique genetic sequences or expression constructs.
2. Patent Families and Filing Strategies
Patent families extend KR20150081339’s protection horizon. Several counterparts are filed internationally, leveraging the Patent Cooperation Treaty (PCT) or regional routes, thus broadening enforcement potential.
The strategic filing suggests a focus on protecting core production methods in key markets, including North America and Europe, in addition to South Korea.
3. Overlap and Potential Conflicts
Overlap with prior art exists where general recombinant expression methods are claimed. However, claims emphasizing specific engineered genetic elements combined with tailored fermentation parameters aim to carve out patentability and defend against invalidation challenges.
4. Patent Challenges and Legal Status
As of the latest updates, KR20150081339 remains in force, with some opposition or patent office actions possible due to the high competitive nature of bioprocess patents.
Implications for Industry and Innovation
- Competitive Edge: The claims' specificity concerning genetic sequences and process parameters potentially afford a strong patent barrier, preventing competitors from similarly optimizing production methods.
- Freedom to Operate (FTO): Companies must carefully navigate these claims, particularly if their processes employ similar genetic constructs or fermentation techniques.
- Research and Development: The patent indicates ongoing innovation in genetic engineering and process optimization, aligning with global trends toward more efficient biotherapeutic manufacturing.
Conclusion
KR20150081339 strategically delineates a proprietary method for producing proteins and peptides with potentially significant commercial and therapeutic value. Its claims center on innovative genetic constructs and optimized fermentation processes, forming a robust patent barrier in the biotech landscape. While overlapping with prior art exists, the specific combination of genetic sequencing and process conditions likely sustains its validity and enforceability.
Key Takeaways
- KR20150081339’s scope emphasizes genetic modifications coupled with optimized fermentation and purification techniques, providing a comprehensive method for protein/peptide production.
- The patent’s claims, while building on existing biotechnological foundations, likely include novel genetic elements and process specifics that strengthen its patentability.
- A broad patent landscape strategy underscores the importance of this patent in South Korea and internationally; competitors should scrutinize its claims to avoid infringement.
- Companies seeking to develop similar biologics must perform detailed freedom-to-operate analyses considering the genetic and process claims.
- As the field advances toward personalized medicine and biologics, such patents will play a critical role in protecting innovative manufacturing methods.
FAQs
Q1: What makes the method claimed in KR20150081339 innovative compared to prior art?
The patent combines specific genetic constructs with tailored fermentation conditions, which together improve yield, purity, or efficiency of protein/peptide production beyond what prior art achieves.
Q2: How broad are the claims concerning the genetic sequences used?
The claims specify particular genetic elements, such as promoters and vectors, but may include the use of certain sequences, making the scope precise but potentially susceptible to design-around efforts.
Q3: Does this patent cover therapeutic proteins directly?
While primarily covering production methods, claims related to the resulting proteins or peptides may implicitly or explicitly cover therapeutic applications, depending on claim language.
Q4: How does this patent landscape influence competition in South Korea?
It consolidates rights around advanced production techniques, discouraging competitors from using similar genetic and process innovations without licensing or design-around strategies.
Q5: Are there ongoing legal disputes or oppositions concerning KR20150081339?
Current public records do not indicate active disputes; however, given the industry’s competitive nature, future challenges are plausible.
Sources
[1] Korean Intellectual Property Office (KIPO) Patent Search Database
[2] World Intellectual Property Organization (WIPO) Patent Data
[3] Patent document KR20150081339, available via KIPO
[4] Industry analysis reports on biotechnological patent trends
